55656-32-1

Basic information

• Product Name: 5-Methyl[1,3]oxazolo[4,5-b]pyridine-2-thiol
• Synonyms: 5-Methyl[1,3]oxazolo[4,5-b]pyridine-2-thiol;5-methyl-3H-[1,3]oxazolo[4,5-b]pyridine-2-thione;5-methyl-3H-oxazolo[4,5-b]pyridine-2-thione;5-Methyl-oxazolo[4,5-b]pyridine-2-thiol
• CAS NO: 55656-32-1
• Molecular Formula: C₇H₆N₂OS
• Molecular Weight: 166.20034
• Mol File: 55656-32-1.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-Methyl[1,3]oxazolo[4,5-b]pyridine-2-thiol(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Methyl[1,3]oxazolo[4,5-b]pyridine-2-thiol(55656-32-1)
• EPA Substance Registry System: 5-Methyl[1,3]oxazolo[4,5-b]pyridine-2-thiol(55656-32-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 55656-32-1(Hazardous Substances Data)

Upstream product

• 140-89-6 potassium ethyl xanthogenate 
• 20348-16-7 2-amino-3-hydroxy-6-methylpyridine 
• 15128-90-2 6-methyl-2-nitropyridin-3-ol 
• 75-15-0 carbon disulfide 

Downstream Products

• 78771-20-7 N-(6-Methyl-3-hydroxy-2-pyridyl)-N-benzylthiourea 
• 78757-34-3 1-Cyclohexyl-3-(3-hydroxy-6-methyl-pyridin-2-yl)-thiourea 

Relevant articles and documents

Fragment-Based Drug Discovery of Inhibitors of Phosphopantetheine Adenylyltransferase from Gram-Negative Bacteria

The discovery and development of new antibiotics capable of curing infections due to multidrug-resistant and pandrug-resistant Gram-negative bacteria are a major challenge with fundamental importance to our global healthcare system. Part of our broad program at Novartis to address this urgent, unmet need includes the search for new agents that inhibit novel bacterial targets. Here we report the discovery and hit-to-lead optimization of new inhibitors of phosphopantetheine adenylyltransferase (PPAT) from Gram-negative bacteria. Utilizing a fragment-based screening approach, we discovered a number of unique scaffolds capable of interacting with the pantetheine site of E. coli PPAT and inhibiting enzymatic activity, including triazolopyrimidinone 6. Structure-based optimization resulted in the identification of two lead compounds as selective, small molecule inhibitors of bacterial PPAT: triazolopyrimidinone 53 and azabenzimidazole 54 efficiently inhibited E. coli and P. aeruginosa PPAT and displayed modest cellular potency against the efflux-deficient E. coli ΔtolC mutant strain.

NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF

Disclosed are novel piperazine derivatives that act as agonists of the α7 nAChR. Also disclosed are phannaceutical compositions, methods of treating inflammatory conditions, methods of treating CNS disorders, methods for inhibiting cytokine release from mammalian cells and methods for the preparation of the novel compounds.

Pharmaceutical compositions for CNS and other disorders

The present invention relates to a method of treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal a CNS-penetrant α7 nicotinic receptor agonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and a CNS-penetrant α7 nicotinic receptor agonist.